Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
MYPI2025002433A0Undetermined Publication Date: 2020-06-07TILLOTS PHARMA AG
0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025002433
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-07
- Filing Date
- 2019-12-06
- Publication Date
- 2020-06-07
Abstract
The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events. No Suitable Fig.
Need to check novelty before this filing date? Find Prior Art
